Reimagining
what’s possible for
type 1 diabetes
At SAB BIO, we believe changing the future starts with thinking differently. We’re committed to redefining what a type 1 diabetes (T1D) diagnosis means with a novel disease-modifying therapy.
About Us
We’re revolutionizing the treatment paradigm in T1D
At SAB BIO, our mission is singular: to dramatically redefine what it means to be diagnosed with T1D by developing a medicine to change the course of disease, not just treat symptoms. Every decision we make—scientific, clinical, and operational—is grounded in that commitment.
SAB-142
is an investigational therapy designed to potentially reduce overreactive immune response to preserve beta cells and their function over time.
Pipeline
T1D is where we
start, not where
we end
Our focus today is advancing SAB-142 as a potential best-in-class, disease-modifying therapy for T1D. It is currently in a pivotal Phase 2b trial for Stage 3 T1D. Looking ahead, we believe our platform has the opportunity to transform the treatment of autoimmune diseases more broadly.
Proprietary antibody technology
We developed a proprietary technology capable of generating a diverse repertoire of multispecific, targeted, fully human immunoglobulins.
Platform
A platform built
differently
We produce SAB-142 using our proprietary platform, which allows us to generate fully human, multispecific antibodies. SAB-142 is designed to reduce the overreactive immune responses associated with autoimmunity and preserve beta cells that produce insulin with the goal of delaying disease progression in autoimmune T1D.
Patients
Every decision starts
with patients
Everything we do is driven by the people living with T1D and the caregivers who support them. Your stories inspire our commitment to make diabetes easier to manage and improve lives.
Investors & Media
The latest from SAB BIO
SAB BIO to Participate in Upcoming Investor Conferences (opens in a new tab)
MIAMI, Nov. 09, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights (opens in a new tab)
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall…
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET (opens in a new tab)
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human…
